BiotechTube
Neurim Pharmaceuticals

Neurim Pharmaceuticals

Basel, Switzerland· Est.
neurim.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Neurim Pharmaceuticals is a private, commercial-stage biotech company with a long-standing focus on CNS disorders, particularly those related to sleep and circadian rhythms. Founded by neuroscientist Nava Zisapel and entrepreneur Yehuda Zisapel, the company has built a commercial footprint with its approved drugs Circadin and Slenyto, which are marketed in over 40 countries. Neurim is leveraging its expertise to expand into adjacent therapeutic areas like Alzheimer's dementia and sleep apnea through internal R&D and strategic partnerships. The company operates with a hybrid business model of direct commercialization and out-licensing.

InsomniaAutism Spectrum Disorder (ASD)Alzheimer's DiseaseSleep Apnea

Technology Platform

Platform centered on modulation of the melatoninergic system and circadian biology, with expertise in melatonin receptor pharmacology and prolonged-release drug delivery formulations to mimic physiological release patterns.

Funding History

1
UndisclosedUndisclosed

Opportunities

Large and growing markets in insomnia, Alzheimer's, and sleep apnea present significant expansion opportunities.
The company's first-mover advantage with circadian-based therapies and its approved niche product for pediatric ASD insomnia provide strong commercial footholds.
Strategic partnerships for co-development and global distribution can accelerate growth and reduce capital requirements.

Risk Factors

High clinical development risk in challenging CNS areas like Alzheimer's disease.
Revenue dependency on two core marketed products exposes the company to competition and pricing pressures.
As a private company, access to sufficient capital to fund late-stage pipeline development is a key uncertainty.

Competitive Landscape

In insomnia, Neurim competes with generic melatonin, sedative-hypnotics (e.g., zolpidem), and newer dual orexin receptor antagonists. Its niche in pediatric ASD is less crowded. The Alzheimer's pipeline will face intense competition from large pharma and biotech companies pursuing amyloid, tau, and other novel mechanisms. The sleep apnea pharmacological market is emerging but competitive.

More companies in Small Molecule Drugs →More companies in Switzerland →